Vancomycin: a 50-something-year-old antibiotic we still don't understand
Because a significant proportion of Staphylococcus aureus strains as well as most coagulase-negative staphylococci are resistant to penicillin and semisynthetic beta-lactam drugs, the need for vancomycin and related antibiotics has never been greater. Effective use of vancomycin requires knowledge o...
Gespeichert in:
| Veröffentlicht in: | Cleveland Clinic journal of medicine 2011-07, Vol.78 (7), p.465-471 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 471 |
|---|---|
| container_issue | 7 |
| container_start_page | 465 |
| container_title | Cleveland Clinic journal of medicine |
| container_volume | 78 |
| creator | Schilling, Amy Neuner, Elizabeth Rehm, Susan J |
| description | Because a significant proportion of Staphylococcus aureus strains as well as most coagulase-negative staphylococci are resistant to penicillin and semisynthetic beta-lactam drugs, the need for vancomycin and related antibiotics has never been greater. Effective use of vancomycin requires knowledge of dosing parameters and selection of target trough levels appropriate to the specific infection and to the pathogen being treated. For clinicians, it is vital to remain up-to-date with evolving definitions for vancomycin susceptibility, with new interpretations of efficacy, and with information on toxicity. |
| doi_str_mv | 10.3949/ccjm.78a.10168 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_874896653</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>874896653</sourcerecordid><originalsourceid>FETCH-LOGICAL-p140t-e8be22c44c27bb19bebc38b7e4ba8a9552178a35bfaf5c647055be2dd19e7ec03</originalsourceid><addsrcrecordid>eNo1jz1PwzAYhC0kREthZUTZOrnYjh3bbKgCilSJBVgjf7wFV4kdYkeo_55KlOmW5x7dIXRDyarWXN85t-9XUpkVJbRRZ2hOda0xU42eocuc94QwQZm-QDNGJeOa6TnafJjoUn9wId5XphIE59RD-QrxEx_AjDh1vjKxBBtSCa76gSqX0HWVT3FZqil6GHMx0V-h853pMlyfcoHenx7f1hu8fX1-WT9s8UA5KRiUBcYc545Ja6m2YF2trARujTJaiOM0ZWphd2YnXMMlEeLY8J5qkOBIvUDLP-8wpu8Jcmn7kB10nYmQptwqyZVuGlEfydsTOdkefDuMoTfjof0_X_8CZFRasg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>874896653</pqid></control><display><type>article</type><title>Vancomycin: a 50-something-year-old antibiotic we still don't understand</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Schilling, Amy ; Neuner, Elizabeth ; Rehm, Susan J</creator><creatorcontrib>Schilling, Amy ; Neuner, Elizabeth ; Rehm, Susan J</creatorcontrib><description>Because a significant proportion of Staphylococcus aureus strains as well as most coagulase-negative staphylococci are resistant to penicillin and semisynthetic beta-lactam drugs, the need for vancomycin and related antibiotics has never been greater. Effective use of vancomycin requires knowledge of dosing parameters and selection of target trough levels appropriate to the specific infection and to the pathogen being treated. For clinicians, it is vital to remain up-to-date with evolving definitions for vancomycin susceptibility, with new interpretations of efficacy, and with information on toxicity.</description><identifier>EISSN: 1939-2869</identifier><identifier>DOI: 10.3949/ccjm.78a.10168</identifier><identifier>PMID: 21724929</identifier><language>eng</language><publisher>United States</publisher><subject>Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - therapeutic use ; Area Under Curve ; Drug Therapy, Combination ; Humans ; Methicillin-Resistant Staphylococcus aureus - drug effects ; Microbial Sensitivity Tests ; Staphylococcal Infections - drug therapy ; Vancomycin - administration & dosage ; Vancomycin - adverse effects ; Vancomycin - therapeutic use</subject><ispartof>Cleveland Clinic journal of medicine, 2011-07, Vol.78 (7), p.465-471</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21724929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schilling, Amy</creatorcontrib><creatorcontrib>Neuner, Elizabeth</creatorcontrib><creatorcontrib>Rehm, Susan J</creatorcontrib><title>Vancomycin: a 50-something-year-old antibiotic we still don't understand</title><title>Cleveland Clinic journal of medicine</title><addtitle>Cleve Clin J Med</addtitle><description>Because a significant proportion of Staphylococcus aureus strains as well as most coagulase-negative staphylococci are resistant to penicillin and semisynthetic beta-lactam drugs, the need for vancomycin and related antibiotics has never been greater. Effective use of vancomycin requires knowledge of dosing parameters and selection of target trough levels appropriate to the specific infection and to the pathogen being treated. For clinicians, it is vital to remain up-to-date with evolving definitions for vancomycin susceptibility, with new interpretations of efficacy, and with information on toxicity.</description><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Area Under Curve</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Methicillin-Resistant Staphylococcus aureus - drug effects</subject><subject>Microbial Sensitivity Tests</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Vancomycin - administration & dosage</subject><subject>Vancomycin - adverse effects</subject><subject>Vancomycin - therapeutic use</subject><issn>1939-2869</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jz1PwzAYhC0kREthZUTZOrnYjh3bbKgCilSJBVgjf7wFV4kdYkeo_55KlOmW5x7dIXRDyarWXN85t-9XUpkVJbRRZ2hOda0xU42eocuc94QwQZm-QDNGJeOa6TnafJjoUn9wId5XphIE59RD-QrxEx_AjDh1vjKxBBtSCa76gSqX0HWVT3FZqil6GHMx0V-h853pMlyfcoHenx7f1hu8fX1-WT9s8UA5KRiUBcYc545Ja6m2YF2trARujTJaiOM0ZWphd2YnXMMlEeLY8J5qkOBIvUDLP-8wpu8Jcmn7kB10nYmQptwqyZVuGlEfydsTOdkefDuMoTfjof0_X_8CZFRasg</recordid><startdate>201107</startdate><enddate>201107</enddate><creator>Schilling, Amy</creator><creator>Neuner, Elizabeth</creator><creator>Rehm, Susan J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201107</creationdate><title>Vancomycin: a 50-something-year-old antibiotic we still don't understand</title><author>Schilling, Amy ; Neuner, Elizabeth ; Rehm, Susan J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p140t-e8be22c44c27bb19bebc38b7e4ba8a9552178a35bfaf5c647055be2dd19e7ec03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Area Under Curve</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Methicillin-Resistant Staphylococcus aureus - drug effects</topic><topic>Microbial Sensitivity Tests</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Vancomycin - administration & dosage</topic><topic>Vancomycin - adverse effects</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schilling, Amy</creatorcontrib><creatorcontrib>Neuner, Elizabeth</creatorcontrib><creatorcontrib>Rehm, Susan J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cleveland Clinic journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schilling, Amy</au><au>Neuner, Elizabeth</au><au>Rehm, Susan J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vancomycin: a 50-something-year-old antibiotic we still don't understand</atitle><jtitle>Cleveland Clinic journal of medicine</jtitle><addtitle>Cleve Clin J Med</addtitle><date>2011-07</date><risdate>2011</risdate><volume>78</volume><issue>7</issue><spage>465</spage><epage>471</epage><pages>465-471</pages><eissn>1939-2869</eissn><abstract>Because a significant proportion of Staphylococcus aureus strains as well as most coagulase-negative staphylococci are resistant to penicillin and semisynthetic beta-lactam drugs, the need for vancomycin and related antibiotics has never been greater. Effective use of vancomycin requires knowledge of dosing parameters and selection of target trough levels appropriate to the specific infection and to the pathogen being treated. For clinicians, it is vital to remain up-to-date with evolving definitions for vancomycin susceptibility, with new interpretations of efficacy, and with information on toxicity.</abstract><cop>United States</cop><pmid>21724929</pmid><doi>10.3949/ccjm.78a.10168</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1939-2869 |
| ispartof | Cleveland Clinic journal of medicine, 2011-07, Vol.78 (7), p.465-471 |
| issn | 1939-2869 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_874896653 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Area Under Curve Drug Therapy, Combination Humans Methicillin-Resistant Staphylococcus aureus - drug effects Microbial Sensitivity Tests Staphylococcal Infections - drug therapy Vancomycin - administration & dosage Vancomycin - adverse effects Vancomycin - therapeutic use |
| title | Vancomycin: a 50-something-year-old antibiotic we still don't understand |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T08%3A25%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vancomycin:%20a%2050-something-year-old%20antibiotic%20we%20still%20don't%20understand&rft.jtitle=Cleveland%20Clinic%20journal%20of%20medicine&rft.au=Schilling,%20Amy&rft.date=2011-07&rft.volume=78&rft.issue=7&rft.spage=465&rft.epage=471&rft.pages=465-471&rft.eissn=1939-2869&rft_id=info:doi/10.3949/ccjm.78a.10168&rft_dat=%3Cproquest_pubme%3E874896653%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=874896653&rft_id=info:pmid/21724929&rfr_iscdi=true |